NCT02428491已完成3 期
Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, and 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 354
- 试验地点
- 1
- 主要终点
- Number of Participants Reporting Solicited Injection Site Reactions or Solicited Systemic Reactions
研究概览
简要总结
The purpose of this study is to describe the immunogenicity and safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T fully liquid combined hexavalent vaccine (Hexaxim®) administered at 2, 3, and 4 months of age and at 16 to 17 months of age in infants and toddlers who received a dose of Hep B vaccine at birth or within 1 week after birth.
Primary Objective:
- To describe the safety profile after each and all doses of Sanofi-Pasteur's DTaP-IPV-Hep B-PRP-T combined vaccine in Vietnamese infants and toddlers.
Secondary Objective:
- To demonstrate the non-inferiority of the immune response to all antigens induced by the study vaccine in Vietnamese infants one month after the third dose in a 3-dose primary series with the immune response to all antigens induced by the same study vaccine outside Vietnam.
- To evaluate the immunogenicity of the study vaccine one month after the 3-dose primary series.
- To describe the persistence of all antibodies before receipt of the booster vaccination.
- To evaluate the immunogenicity of the study vaccine one month after the booster.
详细描述
Participants will receive a total of 5 doses of Hep B: One dose of Hep B monovalent vaccine given at birth or within 1 week after birth followed by 3 doses of the Sanofi Pasteur's hexavalent vaccine given as primary series at 2, 3, and 4 months of age and then a booster dose at 16 to 17 months of age, to comply with Vietnamese vaccination recommendations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 61 Days 至 91 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 61 to 91 days on the day of the first study visit
- •Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥2.5 kg
- •Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations)
- •Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures
- •Have received one dose of Hep B vaccine at birth or within 1 week after birth (documented according to the national recommendations).
排除标准
- •Participation in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any other vaccine within the period from 8 days before to 8 days after each subsequent trial vaccination except for Bacille Calmette Guerin (BCG) vaccination (any administration of oral poliovirus vaccine (OPV) in the context of oral poliovirus vaccine-national immunization days (NIDs) does not fall within the scope of this exclusion criterion)
- •Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B (except the dose of Hep B vaccine given at birth or within 1 week after birth) diseases or Haemophilus influenzae type b infection with either the trial vaccine or another vaccine (any administration of OPV in the context of OPV-NIDs does not fall within the scope of this exclusion criterion)
- •Past or current receipt of immune globulins, blood or blood-derived products or planned administration during the trial
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks since birth)
- •History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Haemophilus influenzae type b infections (confirmed either clinically, serologically or microbiologically)
- •Known personal or maternal history of Human Immunodeficiency Virus (HIV), or hepatitis C seropositivity
- •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
- •Known thrombocytopenia, as reported by the parent/legally acceptable representative
- •Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
- •History of seizures
- •In an emergency setting, or hospitalized involuntarily
- •Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- •Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
- •Identified as a natural or adopted child of the Investigator, relatives or employee with direct involvement in the proposed study.
结局指标
主要结局
Number of Participants Reporting Solicited Injection Site Reactions or Solicited Systemic Reactions
时间窗: Within 7 days after vaccination
Solicited injection site reactions: tenderness, erythema, and swelling (and extensive limb swelling for booster dose). Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability
次要结局
- Number of Subjects With Seroprotection/Seroconversion/Vaccine and Booster Response Before and After Booster Vaccination in Cohort 1(Day 425 (pre-booster) and Day 455 (1 month after booster dose))
- Geometric Mean Titers or Geometric Mean Concentrations of DTaP-IPV-HB-PRP~T Antibodies Before and After Infant Series in Cohort(Day 90 (1 month after third dose))
- Percentage of Subjects With Seroprotection/Seroconversion Rates after Infant Series in Cohort 1 and Group 3 of A3L15 (NCT01105559)(Day 90 (1 month after third dose))
- Number of Subjects With Seroprotection/Seroconversion/Vaccine Response After Infant Series in Cohort 1(Day 90 (1 month after third dose))
- Geometric Mean Titers or Geometric Mean Concentrations of DTaP-IPV-HB-PRP~T Antibodies Before and After Booster Vaccination in Cohort 1(Day 425 (pre-booster) and Day 455 (1 month after booster dose))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsHaemophilus Influenzae Type b InfectionPoliomyelitisPertussisHepatitis BTetanusDiphtheriaNCT02094833Sanofi Pasteur, a Sanofi Company310
已完成
3 期
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsPolioHuman Immunodeficiency Virus InfectionHepatitis BTetanusDiphtheriaPertussisNCT02817451Sanofi Pasteur, a Sanofi Company53
已完成
3 期
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthPoliomyelitisInvasive Hib InfectionsHepatitis BWhooping CoughTetanusDiphtheriaNCT01948193Sanofi Pasteur, a Sanofi Company177
未知
3 期
Immunogenicity and Safety of the DTaP-IPV (sanofi Pasteur Kitasato) Combined Vaccine (DD-687) given subcutaneously as a three-dose primary and booster vaccination versus commercially available DTaP (Kitasato) and Oral Polio Virus (OPV) Vaccines in Infants in JapaProphylaxis of pertussis, diphtheria, tetanus, and poliomyelitis infection.JPRN-jRCT2080221313DAIICHISANKYO Co.,Ltd., Sanofi Aventis KK374
已完成
4 期
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandPoliomyelitisHaemophilus InfectionsDiphtheriaPertussisTetanusNCT00255021Sanofi186